Obermatt
See Similar Stocks →

Dr. Reddy's

NSI:DRREDDY · INE089A01031
PharmaceuticalsX-Large

360

29
EV / EBIT31
Price / Owner Earnings48
Owner Earnings Yield57
Dividend Yield51
Price/Sales49
EV / Gross Profit53
Price/Book61
Return on Capital41
Cash Return on Capital49
Return on Equity41
EBIT Margin25
Gross Profitability25
Cash Conversion58
Accruals17
Owner Earnings Margin34
Sales growth21
Profit Growth86
Long-Term EPS Growth29
Owner Earnings Growth16
Reinvestment68
Price momentum43
Debt load51
Refinancing67
Debt Payback100
Liquidity44
Analyst ratings15
Opinion Changes71
Price Target Upside22
Market mood83
Value Creation10/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Dr. Reddy's clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryIndia
IndustryPharmaceuticals
SizeX-Large
TypePublic Company
ExchangeBSE
Founded1984
Employees15,462
Websitedrreddys.com
ISININE089A01031
Last UpdateApr 2, 2026
Indices
CNX Nifty 50 (India)
Themes
Health DiagnosticsDiabetesNephrologyCardiovascularPain ManagementDermatologyRespiratoryOncologyBiotechnologyHealth CareMedical

Description

Dr. Reddy's Laboratories Limited operates as an integrated global pharmaceutical company. The company’s reportable operating segments are as follows: Global Generics; Pharmaceutical Services and Active Ingredients (‘PSAI’); and Others. Global Gener…

Analysis

Middle-of-the-road

Dr. Reddy's Laboratories Limited is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

The price is expensive. You pay 25.4× its owner earnings: the cash an owner could take out each year, which is in the historically expensive zone. At today's price, the market is assuming roughly 9% yearly growth; analysts expect 5%. The price, in other words, assumes less than the experts do.

The trajectory is tepid and the balance sheet is adequate. The company scores 10/20 on our value-creation score: creating some value.

What to watch: Some accounting patterns deserve a closer look. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
84
2023202420252026

All-time high

84

Jun 2026

All-time low

15

Nov 2025

Average rank

51

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
49
56
62
61
Price/Earnings
61
75
82
63
Price/Book
61
57
62
58
Dividend Yield
51
40
48
42
Value (overall)
66
70
67
59

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Dr. Reddy's with its peers
Glenmark Pharmaceuticals
NSI:GLENMARK
58
CountryIndia
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Divi's Laboratories
NSI:DIVISLAB
52
CountryIndia
IndustryLife Sciences Tools & Services
SizeLarge
Full Stock Analysis →
Torrent Pharmaceuticals
NSI:TORNTPHARM
18
CountryIndia
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Aspen Pharmacare
JNB:APN
22
CountrySouth Africa
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Ipca Laboratories
NSI:IPCALAB
58
CountryIndia
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Granules India
NSI:GRANULES
65
CountryIndia
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →